Oruka Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Oruka Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $38.90M.
- Oruka Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $23.35M.
- Oruka Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-12-31 was $1.17M.
- Oruka Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $42.14M, a 5617.23% increase year-over-year.
- Oruka Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $23.35M, a 51.97% decline from fiscal 2020.
- Oruka Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $48.61M, a 603.52% increase from fiscal 2019.
- Oruka Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2019 was $6.91M, a 102.31% increase from fiscal 2018.
- Oruka Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2018 was $3.42M, a 43.98% decline from fiscal 2017.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $38.90M 10-Q · filed 2026-08-10 | |
| 2021-12-31 | $23.35M 10-K · filed 2023-02-24 | |
| 2021-03-31 | $23.35M 10-Q · filed 2022-10-28 | |
| 2020-12-31 | $1.17M 10-Q · filed 2021-11-02 | $48.61M 10-K · filed 2022-03-14 |
| 2020-09-30 | $42.14M 10-Q · filed 2021-11-02 | |
| 2019-12-31 | $6.91M 10-K · filed 2021-03-18 | |
| 2019-09-30 | $737.00K 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $3.26M 10-Q · filed 2020-11-02 | |
| 2019-03-31 | $2.90M 10-Q · filed 2020-11-02 | |
| 2018-12-31 | $3.42M 10-K · filed 2020-02-18 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $7.33M derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-03-31 | $3.42M 10-Q · filed 2019-11-06 | $9.44M derived: sum of 4 quarters · filed 2019-11-06 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $6.10M 10-K · filed 2019-02-27 |
| 2017-09-30 | $3.92M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $2.11M 10-Q · filed 2018-11-14 | |
| 2017-03-31 | $69.00K 10-Q · filed 2018-11-14 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | $34.17M 10-K · filed 2017-03-21 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-17 | $7.87M 10-K · filed 2016-03-17 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-19 | $1.42M 10-K · filed 2015-03-19 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13 | |
| 2013-03-31 | $1.42M 10-Q · filed 2013-05-13 | |
| 2012-12-31 | $1.19M 10-Q · filed 2014-05-13 | |
| 2011-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2012-11-13 | $4.02M 10-Q · filed 2012-11-13 |
| 2011-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-08-13 | |
| 2010-12-31 | $7.18M 10-Q · filed 2013-11-13 | |
| 2005-12-31 | $1.00K 10-Q · filed 2014-05-13 | |
| 2004-12-31 | $7.00K 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |